Austin, Texas (BUSINESS WIRE) - Today Start Licensing, Inc. (Start) reaffirmed that it controls key patents in Korea and elsewhere that cover animal cloning technology, including the technology used to clone dogs.
RNL Bio Ltd (RNL) previously announced on February 12, 2008 that it was launching a dog cloning service and had signed its first client. More recently it has been reported that RNL is offering cloned cancer-sniffing dogs for commercial sale. RNL is not licensed under Start's patents to engage in these commercial activities.
The patents Start controls include Korean Patent Nos. 10-0533476, 10-0533477, 10-0743006, and 10-0793220 as well as numerous foreign counterparts in the U.S., Europe, Japan and elsewhere. These patents are part of a portfolio of patents and patent applications directed to foundational somatic cell nuclear transfer (SCNT) cloning technology.
Start recently granted a sole, worldwide license under these patents to BioArts International Ltd. for cloning dogs and cats.
"Start will pursue available legal remedies as necessary to protect and preserve its patent rights," said Jonathan Thatcher, President of Start Licensing, "including the remedy of blocking importation of products produced under the patented methods into jurisdictions where such rights are available."
About Start Licensing
Start is a joint venture of Geron Corporation (Nasdaq: GERN) and Exeter Life Sciences, Inc. Start manages and licenses a broad portfolio of intellectual property rights related to animal reproductive technologies, including foundational nuclear transfer cloning technology developed at the Roslin Institute for the cloning of Dolly the sheep.
Start's licensees are on the cutting edge of research and product development in food production, medical applications and many other fields.
Start Licensing, Inc.
Ben Carlson, 202-466-9633 ben@turnerstrategies.com
RNL Bio Ltd (RNL) previously announced on February 12, 2008 that it was launching a dog cloning service and had signed its first client. More recently it has been reported that RNL is offering cloned cancer-sniffing dogs for commercial sale. RNL is not licensed under Start's patents to engage in these commercial activities.
The patents Start controls include Korean Patent Nos. 10-0533476, 10-0533477, 10-0743006, and 10-0793220 as well as numerous foreign counterparts in the U.S., Europe, Japan and elsewhere. These patents are part of a portfolio of patents and patent applications directed to foundational somatic cell nuclear transfer (SCNT) cloning technology.
Start recently granted a sole, worldwide license under these patents to BioArts International Ltd. for cloning dogs and cats.
"Start will pursue available legal remedies as necessary to protect and preserve its patent rights," said Jonathan Thatcher, President of Start Licensing, "including the remedy of blocking importation of products produced under the patented methods into jurisdictions where such rights are available."
About Start Licensing
Start is a joint venture of Geron Corporation (Nasdaq: GERN) and Exeter Life Sciences, Inc. Start manages and licenses a broad portfolio of intellectual property rights related to animal reproductive technologies, including foundational nuclear transfer cloning technology developed at the Roslin Institute for the cloning of Dolly the sheep.
Start's licensees are on the cutting edge of research and product development in food production, medical applications and many other fields.
Start Licensing, Inc.
Ben Carlson, 202-466-9633 ben@turnerstrategies.com
No comments:
Post a Comment